TABLE OF CONTENTS
1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Cancer Immunotherapy Market - By Therapy
1.3.2 Cancer Immunotherapy Market - By Application
1.3.3 Cancer Immunotherapy Market - By End User
1.3.4 Cancer Immunotherapy Market - By Region
1.3.4.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. CANCER IMMUNOTHERAPY MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. CANCER IMMUNOTHERAPY MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS, RESTRAINTS & EXPECTED INFLUENCE OF COVID-19 PANDEMIC
6. CANCER IMMUNOTHERAPY MARKET - GLOBAL MARKET ANALYSIS
6.1. CANCER IMMUNOTHERAPY - GLOBAL MARKET OVERVIEW
6.2. CANCER IMMUNOTHERAPY - GLOBAL MARKET AND FORECAST TO 2027
6.3. MARKET POSITIONING/MARKET SHARE
7. CANCER IMMUNOTHERAPY MARKET - REVENUE AND FORECASTS TO 2027 - THERAPY
7.1. OVERVIEW
7.2. THERAPY MARKET FORECASTS AND ANALYSIS
7.3. MONOCLONAL ANTIBODIES
7.3.1. Overview
7.3.2. Monoclonal Antibodies Market Forecast and Analysis
7.4. IMMUNE CHECKPOINT INHIBITORS
7.4.1. Overview
7.4.2. Immune Checkpoint Inhibitors Market Forecast and Analysis
7.4.3. PD-1/PD-L1 Market
7.4.3.1. Overview
7.4.3.2. PD-1/PD-L1 Market Forecast and Analysis
7.4.4. CTLA-4 Market
7.4.4.1. Overview
7.4.4.2. CTLA-4 Market Forecast and Analysis
7.5. IMMUNE SYSTEM MODULATORS
7.5.1. Overview
7.5.2. Immune System Modulators Market Forecast and Analysis
7.6. CANCER VACCINES
7.6.1. Overview
7.6.2. Cancer Vaccines Market Forecast and Analysis
8. CANCER IMMUNOTHERAPY MARKET - REVENUE AND FORECASTS TO 2027 - APPLICATION
8.1. OVERVIEW
8.2. APPLICATION MARKET FORECASTS AND ANALYSIS
8.3. LUNG CANCER
8.3.1. Overview
8.3.2. Lung Cancer Market Forecast and Analysis
8.4. COLORECTAL CANCER
8.4.1. Overview
8.4.2. Colorectal Cancer Market Forecast and Analysis
8.5. BREAST CANCER
8.5.1. Overview
8.5.2. Breast Cancer Market Forecast and Analysis
8.6. PROSTATE CANCER
8.6.1. Overview
8.6.2. Prostate Cancer Market Forecast and Analysis
8.7. MELANOMA
8.7.1. Overview
8.7.2. Melanoma Market Forecast and Analysis
8.8. HEAD AND NECK CANCER
8.8.1. Overview
8.8.2. Head and neck cancer Market Forecast and Analysis
8.9. OVARIAN CANCER
8.9.1. Overview
8.9.2. Ovarian cancer Market Forecast and Analysis
8.10. OTHERS
8.10.1. Overview
8.10.2. Others Market Forecast and Analysis
9. CANCER IMMUNOTHERAPY MARKET - REVENUE AND FORECASTS TO 2027 - END USER
9.1. OVERVIEW
9.2. END USER MARKET FORECASTS AND ANALYSIS
9.3. HOSPITALS
9.3.1. Overview
9.3.2. Hospitals Market Forecast and Analysis
9.4. AMBULATORY SURGERY CENTERS
9.4.1. Overview
9.4.2. Ambulatory Surgery Centers Market Forecast and Analysis
9.5. CANCER RESEARCH CENTERS
9.5.1. Overview
9.5.2. Cancer Research Centers Market Forecast and Analysis
9.6. SPECIALTY CLINICS
9.6.1. Overview
9.6.2. Specialty Clinics Market Forecast and Analysis
10. CANCER IMMUNOTHERAPY MARKET REVENUE AND FORECASTS TO 2027 - GEOGRAPHICAL ANALYSIS
10.1. NORTH AMERICA
10.1.1 North America Cancer Immunotherapy Market Overview
10.1.2 North America Cancer Immunotherapy Market Forecasts and Analysis
10.1.3 North America Cancer Immunotherapy Market Forecasts and Analysis - By Therapy
10.1.4 North America Cancer Immunotherapy Market Forecasts and Analysis - By Application
10.1.5 North America Cancer Immunotherapy Market Forecasts and Analysis - By End User
10.1.6 North America Cancer Immunotherapy Market Forecasts and Analysis - By Countries
10.1.6.1 United States Cancer Immunotherapy Market
10.1.6.1.1 United States Cancer Immunotherapy Market by Therapy
10.1.6.1.2 United States Cancer Immunotherapy Market by Application
10.1.6.1.3 United States Cancer Immunotherapy Market by End User
10.1.6.2 Canada Cancer Immunotherapy Market
10.1.6.2.1 Canada Cancer Immunotherapy Market by Therapy
10.1.6.2.2 Canada Cancer Immunotherapy Market by Application
10.1.6.2.3 Canada Cancer Immunotherapy Market by End User
10.1.6.3 Mexico Cancer Immunotherapy Market
10.1.6.3.1 Mexico Cancer Immunotherapy Market by Therapy
10.1.6.3.2 Mexico Cancer Immunotherapy Market by Application
10.1.6.3.3 Mexico Cancer Immunotherapy Market by End User
10.2. EUROPE
10.2.1 Europe Cancer Immunotherapy Market Overview
10.2.2 Europe Cancer Immunotherapy Market Forecasts and Analysis
10.2.3 Europe Cancer Immunotherapy Market Forecasts and Analysis - By Therapy
10.2.4 Europe Cancer Immunotherapy Market Forecasts and Analysis - By Application
10.2.5 Europe Cancer Immunotherapy Market Forecasts and Analysis - By End User
10.2.6 Europe Cancer Immunotherapy Market Forecasts and Analysis - By Countries
10.2.6.1 Germany Cancer Immunotherapy Market
10.2.6.1.1 Germany Cancer Immunotherapy Market by Therapy
10.2.6.1.2 Germany Cancer Immunotherapy Market by Application
10.2.6.1.3 Germany Cancer Immunotherapy Market by End User
10.2.6.2 France Cancer Immunotherapy Market
10.2.6.2.1 France Cancer Immunotherapy Market by Therapy
10.2.6.2.2 France Cancer Immunotherapy Market by Application
10.2.6.2.3 France Cancer Immunotherapy Market by End User
10.2.6.3 Italy Cancer Immunotherapy Market
10.2.6.3.1 Italy Cancer Immunotherapy Market by Therapy
10.2.6.3.2 Italy Cancer Immunotherapy Market by Application
10.2.6.3.3 Italy Cancer Immunotherapy Market by End User
10.2.6.4 Spain Cancer Immunotherapy Market
10.2.6.4.1 Spain Cancer Immunotherapy Market by Therapy
10.2.6.4.2 Spain Cancer Immunotherapy Market by Application
10.2.6.4.3 Spain Cancer Immunotherapy Market by End User
10.2.6.5 United Kingdom Cancer Immunotherapy Market
10.2.6.5.1 United Kingdom Cancer Immunotherapy Market by Therapy
10.2.6.5.2 United Kingdom Cancer Immunotherapy Market by Application
10.2.6.5.3 United Kingdom Cancer Immunotherapy Market by End User
10.3. ASIA-PACIFIC
10.3.1 Asia-Pacific Cancer Immunotherapy Market Overview
10.3.2 Asia-Pacific Cancer Immunotherapy Market Forecasts and Analysis
10.3.3 Asia-Pacific Cancer Immunotherapy Market Forecasts and Analysis - By Therapy
10.3.4 Asia-Pacific Cancer Immunotherapy Market Forecasts and Analysis - By Application
10.3.5 Asia-Pacific Cancer Immunotherapy Market Forecasts and Analysis - By End User
10.3.6 Asia-Pacific Cancer Immunotherapy Market Forecasts and Analysis - By Countries
10.3.6.1 Australia Cancer Immunotherapy Market
10.3.6.1.1 Australia Cancer Immunotherapy Market by Therapy
10.3.6.1.2 Australia Cancer Immunotherapy Market by Application
10.3.6.1.3 Australia Cancer Immunotherapy Market by End User
10.3.6.2 China Cancer Immunotherapy Market
10.3.6.2.1 China Cancer Immunotherapy Market by Therapy
10.3.6.2.2 China Cancer Immunotherapy Market by Application
10.3.6.2.3 China Cancer Immunotherapy Market by End User
10.3.6.3 India Cancer Immunotherapy Market
10.3.6.3.1 India Cancer Immunotherapy Market by Therapy
10.3.6.3.2 India Cancer Immunotherapy Market by Application
10.3.6.3.3 India Cancer Immunotherapy Market by End User
10.3.6.4 Japan Cancer Immunotherapy Market
10.3.6.4.1 Japan Cancer Immunotherapy Market by Therapy
10.3.6.4.2 Japan Cancer Immunotherapy Market by Application
10.3.6.4.3 Japan Cancer Immunotherapy Market by End User
10.3.6.5 South Korea Cancer Immunotherapy Market
10.3.6.5.1 South Korea Cancer Immunotherapy Market by Therapy
10.3.6.5.2 South Korea Cancer Immunotherapy Market by Application
10.3.6.5.3 South Korea Cancer Immunotherapy Market by End User
10.4. MIDDLE EAST AND AFRICA
10.4.1 Middle East and Africa Cancer Immunotherapy Market Overview
10.4.2 Middle East and Africa Cancer Immunotherapy Market Forecasts and Analysis
10.4.3 Middle East and Africa Cancer Immunotherapy Market Forecasts and Analysis - By Therapy
10.4.4 Middle East and Africa Cancer Immunotherapy Market Forecasts and Analysis - By Application
10.4.5 Middle East and Africa Cancer Immunotherapy Market Forecasts and Analysis - By End User
10.4.6 Middle East and Africa Cancer Immunotherapy Market Forecasts and Analysis - By Countries
10.4.6.1 South Africa Cancer Immunotherapy Market
10.4.6.1.1 South Africa Cancer Immunotherapy Market by Therapy
10.4.6.1.2 South Africa Cancer Immunotherapy Market by Application
10.4.6.1.3 South Africa Cancer Immunotherapy Market by End User
10.4.6.2 Saudi Arabia Cancer Immunotherapy Market
10.4.6.2.1 Saudi Arabia Cancer Immunotherapy Market by Therapy
10.4.6.2.2 Saudi Arabia Cancer Immunotherapy Market by Application
10.4.6.2.3 Saudi Arabia Cancer Immunotherapy Market by End User
10.4.6.3 U.A.E Cancer Immunotherapy Market
10.4.6.3.1 U.A.E Cancer Immunotherapy Market by Therapy
10.4.6.3.2 U.A.E Cancer Immunotherapy Market by Application
10.4.6.3.3 U.A.E Cancer Immunotherapy Market by End User
10.5. SOUTH AND CENTRAL AMERICA
10.5.1 South and Central America Cancer Immunotherapy Market Overview
10.5.2 South and Central America Cancer Immunotherapy Market Forecasts and Analysis
10.5.3 South and Central America Cancer Immunotherapy Market Forecasts and Analysis - By Therapy
10.5.4 South and Central America Cancer Immunotherapy Market Forecasts and Analysis - By Application
10.5.5 South and Central America Cancer Immunotherapy Market Forecasts and Analysis - By End User
10.5.6 South and Central America Cancer Immunotherapy Market Forecasts and Analysis - By Countries
10.5.6.1 Brazil Cancer Immunotherapy Market
10.5.6.1.1 Brazil Cancer Immunotherapy Market by Therapy
10.5.6.1.2 Brazil Cancer Immunotherapy Market by Application
10.5.6.1.3 Brazil Cancer Immunotherapy Market by End User
10.5.6.2 Argentina Cancer Immunotherapy Market
10.5.6.2.1 Argentina Cancer Immunotherapy Market by Therapy
10.5.6.2.2 Argentina Cancer Immunotherapy Market by Application
10.5.6.2.3 Argentina Cancer Immunotherapy Market by End User
11. INDUSTRY LANDSCAPE
11.1. MERGERS AND ACQUISITIONS
11.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
11.3. NEW PRODUCT LAUNCHES
11.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
12. CANCER IMMUNOTHERAPY MARKET, KEY COMPANY PROFILES
12.1. F. HOFFMANN-LA ROCHE AG
12.1.1. Key Facts
12.1.2. Business Description
12.1.3. Products and Services
12.1.4. Financial Overview
12.1.5. SWOT Analysis
12.1.6. Key Developments
12.2. ADVAXIS INC.
12.2.1. Key Facts
12.2.2. Business Description
12.2.3. Products and Services
12.2.4. Financial Overview
12.2.5. SWOT Analysis
12.2.6. Key Developments
12.3. MERCK AND CO., INC.
12.3.1. Key Facts
12.3.2. Business Description
12.3.3. Products and Services
12.3.4. Financial Overview
12.3.5. SWOT Analysis
12.3.6. Key Developments
12.4. ELI LILLY AND COMPANY
12.4.1. Key Facts
12.4.2. Business Description
12.4.3. Products and Services
12.4.4. Financial Overview
12.4.5. SWOT Analysis
12.4.6. Key Developments
12.5. BRISTOL-MYERS SQUIBB COMPANY
12.5.1. Key Facts
12.5.2. Business Description
12.5.3. Products and Services
12.5.4. Financial Overview
12.5.5. SWOT Analysis
12.5.6. Key Developments
12.6. PFIZER INC.
12.6.1. Key Facts
12.6.2. Business Description
12.6.3. Products and Services
12.6.4. Financial Overview
12.6.5. SWOT Analysis
12.6.6. Key Developments
12.7. NOVARTIS AG
12.7.1. Key Facts
12.7.2. Business Description
12.7.3. Products and Services
12.7.4. Financial Overview
12.7.5. SWOT Analysis
12.7.6. Key Developments
12.8. BAYER AG
12.8.1. Key Facts
12.8.2. Business Description
12.8.3. Products and Services
12.8.4. Financial Overview
12.8.5. SWOT Analysis
12.8.6. Key Developments
12.9. IMMUNOMEDICS INC.
12.9.1. Key Facts
12.9.2. Business Description
12.9.3. Products and Services
12.9.4. Financial Overview
12.9.5. SWOT Analysis
12.9.6. Key Developments
12.10. ASTRAZENECA PLC.
12.10.1. Key Facts
12.10.2. Business Description
12.10.3. Products and Services
12.10.4. Financial Overview
12.10.5. SWOT Analysis
12.10.6. Key Developments
13. APPENDIX
13.1. ABOUT THE INSIGHT PARTNERS
13.2. GLOSSARY OF TERMS